tbuckley/cabot-search huggingface dataset:
SAT0113 Common trajectories of HAQ disability progression over 15-years in the early rheumatoid arthritis study and the norfolk arthritis register
Authors: S. Norton, B. Fu, S.M.M. Verstappen, D.P.M. Symmons, M. Lunt, R. Davies, D.L. Scott, C. Deighton, A.J. Wailoo, J. Tosh, A. Young
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The Health Assessment Questionnaire (HAQ) is the most widely used measure of function in studies of inflammatory polyarthritis (IP) and its subset rheumatoid arthritis (RA). Previous research has suggested the mean HAQ over time is j-shaped with an initial improvement followed by an insidious decline. Few studies have attempted to identify distinct subgroups with common HAQ trajectories in IP and RA samples, or considered their validity across cohorts. <h3>Objectives</h3> To identify common trajectories of HAQ progression in two large prospective observational studies. <h3>Methods</h3> Data of two large inception cohorts, the Early Rheumatoid Arthritis Study (ERAS) and the Norfolk Arthritis Register (NOAR), were used. ERAS recruited patients with RA from 9 hospital clinics in England between 1986 and 1997: N=1460, mean age 55yrs, 66% female, mean symptom duration 8mths. NOAR is a primary care based inception cohort of early IP in Norwich, England. Patients recruited between 1990 and 1994 were included: N=1027, mean age 53yrs, 66% female, mean symptom duration 9mths. In both cohorts, disease activity and HAQ-scores are measured at baseline and at subsequent follow-up visits. To determine trajectories of HAQ progression over time, latent class growth models (LCGM) were applied to the datasets separately. Age, sex, baseline DAS, symptom duration, rheumatoid factor, and fulfillment of ACR criteria were included as predictors of class membership. <h3>Results</h3> In both cohorts a 4 class LCGM was selected as providing the best fit. The classes identified were similar in terms of the shape of the trajectories and distribution of patients between classes (see figure). Three classes exhibited a j-shaped trajectory. A fourth class experienced persistently high HAQ that increased early in the course of the disease. In both cohorts older age, female sex, longer symptom duration, fulfillment of ACR criteria and higher DAS were associated with increased likelihood of membership of classes with worse HAQ progression. <h3>Conclusions</h3> Four subgroups with common HAQ trajectories were derived from the ERAS and NOAR cohorts. That the subgroups identified were nearly identical supports their validity. Identifying distinct groups of patients at risk of poor functional outcome may help to target therapy to those most likely to benefit. <h3>Disclosure of Interest</h3> None Declared
Malrotation of the Gastrointestinal Tract Mimicking a Bile Leak
Authors: JAMES D. PATRIZI, STEPHEN R. DELONG
Journal: Clinical Nuclear Medicine (1997)

A 41-year-old man presented with vague abdominal pain and watery diarrhea. Ultrasound demonstrated cholelithiasis. A hepatobiliary scan was performed demonstrating filling of the gallbladder. Unusual activity is seen along the inferior aspect of the liver, extending from the gallbladder. The possibility of a bile leak was considered. Delayed images show this activity to be within the bowel. A barium study shows complete malrotation of the small bowel. The patient underwent laparoscopic cholecystectomy and pathology showed chronic cholecystitis.
Human Growth Hormone
Authors: Andrew G. Frantz, Mitchell T. Rabkin
Journal: New England Journal of Medicine (1964)

THE recent isolation of human growth hormone from pituitary glands collected at autopsy has been of major importance in the investigation of human pituitary physiology.1 , 2 Metabolic studies have confirmed the remarkable anabolic and growth-promoting actions of this hormone in man,3 , 4 in contrast to the negative or equivocal clinical results previously observed with bovine growth hormone. The unusually high species specificity of human growth hormone has been further demonstrated by immunologic studies, in which antigenic similarity and biologic effectiveness have closely paralleled one another among various mammalian species.5 An assay taking advantage of immunologic specificity was first reported by Read and . . .
PARE0004 The Leap in Technical Developement in Estonian RHEUMATISM Association
Authors: S. Viljaste
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> In today9s hasty but well-functioning society it is clear that non-profit organizations such as Estonian Rheumatism Association should always make efforts towards sustainability and to preserve it9s status as a modern organization. Therefore it is necessary to keep our board members, management team, voulenteers and member unions informed about the latest changes in technology we are using today. It is not just about updating the hardware but also to improve operational capabilities through telecommunication, self-realization and digital literacy. For that matter, Estonian Rheumatism Association has started a project on year 2014 such as "The leap in technical developement in non-profit organization" which is funded by Enterprise Estonia. The intention of this project is to improve better understanding of the general public about the relations between umbrella organization and sub-organizations. Right now one of the main reasons that are slowing down our capability for actions are mainly the lack of technical preparation and the lack of digital literacy or insufficient knowledge about menegement among the Heads of our member organizations and unstable funding from the government. <h3>Objectives</h3> The main goal of the project is to promote co-operation between umbrella organization and their members, also to provide quality information for patients with rheumatic diseases, their families, supporters and health care professionals. In the process of project research it is important to clarify current situation - our strengths and weaknesses, threats and opportunities and members expectations about the future. The results drawn from the research are being used as an input for strategic plan and developing the membership program for umbrella organization. All the activities are planned to strengthen inside and outside communication, co-operation and team work, also to be more active in civil society on local and national level. <h3>Methods</h3> The leap in developement related to digital literacy is achieved by reducing the gaps between management team and Heads of the member organizations. We are also determining what technical assets and technologies are needed to fulfill our objectives. Last but not least, we are trying to find solutions for improving the mangement skills in order to use them for our member organizations. <h3>Results</h3> We are overcoming from the current poor tecnical contitions and as for a umbrella organization we will have a better overview about the technical readiness in our member oranizations in order to implement the changes. <h3>Conclusions</h3> In conclusion, we hope that the project will increase the awareness in using information as a tool and raise competency in using the basic communication instruments amoung our board members, management team and Heads of member ogranizations. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5244
Outcomes of Rapid Defibrillation by Security Officers after Cardiac Arrest in Casinos
Authors: Terence D. Valenzuela, Denise J. Roe, Graham Nichol, Lani L. Clark, Daniel W. Spaite, Richard G. Hardman
Journal: New England Journal of Medicine (2000)

The use of automated external defibrillators by persons other than paramedics and emergency medical technicians is advocated by the American Heart Association and other organizations. However, there are few data on the outcomes when the devices are used by nonmedical personnel for out-of-hospital cardiac arrest.
Abstract 2360: Cell size and shear stress resistance do not correlate with metastatic efficiency
Authors: James M. Barnes, Michael D. Henry
Journal: Cancer Research (2010)

Abstract Metastasis is the leading cause of death in patients with epithelial cancers. It has been observed both clinically and experimentally that metastasis is a very inefficient process. It is believed that the majority of primary cancer cells entering the bloodstream are cleared rapidly, likely by destruction under hemodynamic shear forces, thus greatly reducing the number of surviving cells which can go on to colonize a secondary site. It would thus seem advantageous for metastatic cancer cells to adapt mechanisms to resist this type of stress. One factor which may influence shear stress susceptibility is cell size; the larger a cell is the more shear stress this cell will experience while in circulation. Here, we report the cell size and shear stress analysis of a panel of well described cancer cell lines and their metastatic derivatives obtained from metastatic lesions in mice. We found no correlation between the ability of a cancer cell to metastasize with a reduction in cell size or an increase in shear force resistance. Our data suggest that the loss of tumor cells by hemodynamic shear force is lower than often estimated. We conclude that the metastatic cascade does not generally select for cells of a smaller size and that shear stress resistance does not predict the aggressiveness of a particular cancer cell line. These findings support the hypothesis that the later steps in metastasis, such as extravasation and colonization, dictate the inefficiency of this process. Interestingly, although metastatic derivatives did not tend to exhibit increased resistance to shear force, there were certainly differences between cancer cell lines of different tissue origin. This fact may become important when designing isolation methods for circulating tumor cells, the analysis of these studies, and the prognostic value of quantifying circulating tumor cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2360.
High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: The EBMT experience
Authors: J W Sweetenham, S J Proctor, D Blaise, A De Laurenzi, R Pearce, G Taghipour, A H Goldstone, A ] Laurenzi A [corrected to De Laurenzi
Journal: Annals of Oncology (1994)
Renin Profiling in Hypertension and Its Use in Treatment with Propranolol and Chlorthalidone
Authors: James W. Woods, A. Wayne Pittman, Charles C. Pulliam, Emile E. Werk, Winfried Waider, Cyril A. Allen
Journal: New England Journal of Medicine (1976)

We compared methods of classifying hypertension according to plasma renin activity in 54 patients with essential hypertension and examined the validity of using these classifications to choose between two hypotensive drugs. A prospective, double-blind crossover study was used. Normal values for plasma renin activity were established from 111 control subjects. Plasma renin activity was related to race and inversely to age in hypertensive patients (P less than 0.05) but not in normal subjects. Three methods of classification correlated well but did not identify exactly the same renin-suppressed patients. Chlorthalidone produced a greater reduction in blood pressure and restored blood pressure to normal in a larger percentage of patients in both low-renin (59 per cent) and normal-renin (32 per cent) subgroups than propranolol (12 and 16 per cent). Renin determinations are of limited benefit in the choice of therapy for most patients with essential hypertension.
Longer Tc-99m-Mebrofenin Labeling-to-Administration Time Results in Scintigraphic Underestimation of Liver Function
Authors: Mark Tulchinsky, Thomas W. Allen
Journal: Clinical Nuclear Medicine (2011)

Tc-99m-mebrofenin clearance rate is used to estimate hepatocellular function. This investigation studied effect of labeling-to-administration (LTA) time of Tc-99m-mebrofenin and its liver clearance rate.A total of 15 patients, age 46 ± 13 (range, 19-69) years, referred for routine gallbladder ejection fraction testing, were retrospectively studied. All had tests associated to normal liver, and no medical history of liver diseases was observed. Tc-99m-mebrofenin scintigraphic liver clearance (MSLC) rate was determined by the standard technique based on liver uptake rate. The radiopharmaceutical was prepared at an off-site central radiopharmacy. Linear regression was used to assess relationship of LTA time and MSLC.The LTA was 7.6 ± 2.0 (range, 4-12) hours. The labeling efficiency was 99.0% ± 1.33%. The MSLC rate was 11.9%/min ± 2.7%/min (range, 6.4-18.3). There was an inverse relationship of LTA and MSLC, expressed in the following equation: y = -0. 97x + 19.25 (R = 0.5076, P = 0.0028). The negative correlation with LTA remained when MSLC was corrected for body surface area (R = 0.4241, P = 0.0085).There is a significant underestimation of MSLC with increasing LTA time. If liver function assessment is the purpose of a hepatobiliary study, Tc-99m-mebrofenin should be administered as close to the time of radiopharmaceutical preparation as possible, preferably within 1 hour.
Randomized Trial of Labor Induction in Women 35 Years of Age or Older
Authors: Kate F. Walker, George J. Bugg, Marion Macpherson, Carol McCormick, Nicky Grace, Chris Wildsmith, Lucy Bradshaw, Gordon C.S. Smith, James G. Thornton
Journal: New England Journal of Medicine (2016)

The risk of antepartum stillbirth at term is higher among women 35 years of age or older than among younger women. Labor induction may reduce the risk of stillbirth, but it also may increase the risk of cesarean delivery, which already is common in this older age group.We conducted a randomized, controlled trial involving primigravid women who were 35 years of age or older. Women were randomly assigned to labor induction between 39 weeks 0 days and 39 weeks 6 days of gestation or to expectant management (i.e., waiting until the spontaneous onset of labor or until the development of a medical problem that mandated induction). The primary outcome was cesarean delivery. The trial was not designed or powered to assess the effects of labor induction on stillbirth.A total of 619 women underwent randomization. In an intention-to-treat analysis, there were no significant between-group differences in the percentage of women who underwent a cesarean section (98 of 304 women in the induction group [32%] and 103 of 314 women in the expectant-management group [33%]; relative risk, 0.99; 95% confidence interval [CI], 0.87 to 1.14) or in the percentage of women who had a vaginal delivery with the use of forceps or vacuum (115 of 304 women [38%] and 104 of 314 women [33%], respectively; relative risk, 1.30; 95% CI, 0.96 to 1.77). There were no maternal or infant deaths and no significant between-group differences in the women's experience of childbirth or in the frequency of adverse maternal or neonatal outcomes.Among women of advanced maternal age, induction of labor at 39 weeks of gestation, as compared with expectant management, had no significant effect on the rate of cesarean section and no adverse short-term effects on maternal or neonatal outcomes. (Funded by the Research for Patient Benefit Programme of the National Institute for Health Research; Current Controlled Trials number, ISRCTN11517275.).
P870 REVERSIBLE NON-ISCHEMIC CARDIOMYOPATHY WITH SEVERE LEFT VENTRICULAR DYSFUNCTION AFTER LIVER TRANSPLANTATION
Authors: M. Yataco, T. Difato, J. Trejo-Gutierrez, T. Patel, B. Rosser, J. Bargehr, S. Pungpapong, B. Taner, J. Aranda-Michel
Journal: Journal of Hepatology (2014)
BCL-2-ASSOCIATED ATHANOGENE 3 CONCENTRATIONS ARE PROGNOSTIC IN PATIENTS WITH ACUTELY DECOMPENSATED HEART FAILURE
Authors: Parul U. Gandhi, Hanna Gaggin, Arianna M. Belcher, Anna Basile, Antonia Falco, Alessandra Rosati, James Januzzi, M. Caterina Turco
Journal: Journal of the American College of Cardiology (2015)
Soft-Tissue Tumor Demonstrated on Radionuclide Venogram
Authors: NYLLA SHANTHLY, REGI OOMMEN
Journal: Clinical Nuclear Medicine (1996)

A 48-year-old man had recurrent episodes of ipsilateral pain and diffuse swelling over the left lower thigh and calf, associated with dilated veins and pitting edema. Deep-vein thrombosis was suspected and radionuclide venogram was performed using Tc-99m RBC imaging. The blood pool scintigram demonstrated diffuse accumulation of RBC in the soft tissues of the left lower thigh, suggestive of a soft-tissue mass and associated with features of venous stasis in the calf. The soft-tissue mass was found to be a primary malignant lymphoma by subsequently obtained biopsy specimens.
REVASCULARIZATION STRATEGIES FOR PATIENTS WITH MULTIPLE VESSEL DISEASE AND UNPROTECTED LEFT MAIN WITH A COBALT-CHROMIUM RAPAMYCIN ELUTING STENT: TWO YEARS RESULTS FROM ERACI IV REGISTRY
Authors: Alfredo Matias Rodriguez-Granillo, Carlos Haiek, Ignacio Rifourcat, Raul Solernó, Miguel Larribau, Carlos Fernandez-Pereira, Juan Mieres, Omar Santaera, Antonio Pocovi, Ricardo Sarmiento, Alfredo Rodriguez
Journal: Journal of the American College of Cardiology (2016)
Abstract 1806: Efficacy of MM121 in ER+ and triple negative breast cancer studies
Authors: Lin Nie, Olga Burenkova, Sharlene Adams, Ashish Kalra, Aaron Fulgham, Dongmei Xiao, Viara Grantcharova, Matt Onsum, Lucia Wille, Sharon Moulis, Gabriela Garcia, Victor Moyo, Bill Kubasek, Ulrik Nielsen
Journal: Cancer Research (2010)

Abstract In women, breast cancer is among the most common cancers and the fifth most common cause of cancer deaths. Due to the heterogeneity of the disease, 10-year progression free survival can vary widely with stage and type from 98% to 10%. We present data showing that MM-121, a fully human monoclonal anti-ErbB3 antibody, is efficacious in studies of both hormone dependent (ER+) and triple negative (ER-,PR-, Low Erb2) breast cancer lines that express the molecular profile consistent with MM-121 response (co-expression of ErbB3 and HRG). Using a combination of computational and experimental approaches, ErbB3 was identified as a critical transducer of oncogenic signaling leading to the development of MM-121, a first in class anti-ErbB3 antibody. We have previously demonstrated that MM-121, when used as a single agent, inhibits heregulin-induced signaling events in human cancer cell lines. Moreover, MM-121 caused dose-dependent inhibition of tumor growth in multiple xenograft models of human cancer, including ovarian, renal cell, pancreatic, lung, and prostate cancer. Estrogen dependent, or ER+ breast cancers, make up about 80% of breast cancers. A standard treatment for ER+ breast cancer includes hormone therapy; however a substantial number of ER+ breast cancers eventually develop resistance requiring additional treatments. Here we show that in ER+ breast cancer cells, MM-121 can block HRG induced ErbB3 activation and VEGF secretion as well as HGF induced pErbB3 in vitro. Additionally, in ER+ breast cancer xenograft models, MM121 is effective in combination with both chemotherapy agents and targeted therapies and may be effective in ER+ breast cancers that are refractory to hormone treatment. The triple negative breast cancers are characterized by poor prognosis, aggressiveness, and reduced responsiveness to standard treatments. MM-121 used as a single agent therapy was able to suppress tumor growth in triple negative primary human tumors, when grown as xenografts suggesting that MM-121 monotherapy may be clinically efficacious in triple negative breast cancers. Together, these data suggest that MM-121, when used as a single agent or in combination with other therapies, could offer significant clinical benefit to both ER+ and triple negative breast cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1806.
SAT0377 Evaluation with densitometry of patients with breast cancer and high risk of fractures after 2 years of treatment
Authors: S. Muñoz Gil, M. Garcia Armario, P. Muñoz Mira, M. Torregrosa Maicas, R. Girones Sarrio, P. Lopez Tendero, T. Mut Dόlera
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> Evaluate the differences with densitometry after 2 years of treatment in patients with breast cancer and a high risk fracture. <h3>Methods</h3> A 2 year duration longitudinal study was done in patients diagnosed with breast cancer sent to the Rheumatology Osteoporosis Unit in Hosptial d’Ontinyent, and required supplements of calcium and vitamin D ± bisphosphonates after a risk fracture study. A register and description of the socio-demographic data was done, as well as the characteristics of the breast tumor, the risk factors of osteoporosis and fragile fractures, the definite diagnosis and the treatment initiated in these patients. Differences between the mean values obtained in the mineral bone density of lumbar, total femoral, and femoral neck, were evaluated with the t-student study. The statistic system employed was SPSS 17.0. <h3>Results</h3> 41 patients were studied, with an average age of 59 years old (37 - 79 years).All of them had a unilateral breast cancer, while none had metastases.The treatments received were: radical mastectomy (61%), radiotherapy (61%), chemotherapy (78%), hormonotherapy (29%), tamoxifen (51%), GnRH analogues (12%) and aromatase inhibitors (88%). Risk factors for osteoporosis are shown on table 1. High risk osteoporosis was diagnosed in 3 patients (7.3%), osteoporosis in 15 patients (36.6%) and osteopenia in 23 patients (56.1%).In spinal x-rays, 49 patients had ≥1 vertebral collapse and 7 of them ≥1 vertebral fracture.Treatment with supplements of calcium and vitamin D was initiated in all patients, and bisphosphonates (either oral or i.v.) in 34 patients, as follow: ibandronate (in 13), risedronate (in 15), alendronate (in 5) and zoledronate (in the remaining one).After 2 years of follow-up, no patient had developed metastases and 82.9% continued with aromatase inhibitors. No patient suffered new vertebral collapse or fracture, and only 1 patient suffered from other fractures. After a 2 year treatment of osteoporosis, 95.1% of the patients continued with the same treatment, and only 2 patients had abandoned it. Results obtained from densitometry pre-treatment and after 2 year treatment, as well as statistical differences by applying t-student test, are shown on table 2. <h3>Conclusions</h3> Patients with breast cancer that require initiating treatment for fragile risk fracture present good treatment compliance. Treatment including supplements of calcium and vitamin D and bisphosphonates during 2 years improves the mineral bone density in all localizations. <h3>Disclosure of Interest</h3> None Declared